Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

Merck/Pfizer Diabetes Drug Ertugliflozin Positive In Phase III

Published 09/15/2016, 09:03 PM
Updated 07/09/2023, 06:31 AM
Merck & Co., Inc. (NYSE:MRK) , in partnership with Pfizer Inc. (NYSE:PFE) , announced that their diabetes pipeline candidate, ertugliflozin (MK-8835), has met the primary endpoint in a phase III study.
The double-blind, randomized, placebo-controlled study, VERTIS SITA2, showed that ertugliflozin (both 5 mg and 15 mg daily doses), when added to sitagliptin and metformin, led to A1C reduction in patients with type 2 diabetes. While the 5-mg dose reduced A1C by 0.69%, the 15 mg dose led to a 0.76% decline in A1C.
Ertugliflozin is an investigational oral sodium glucose cotransporter (SGLT2) inhibitor.
The drug met the key secondary end-points of the trial as well.
Overall adverse event (AE) rates were also low in both the dosage arms of ertugliflozin compared to placebo.
These results were presented at the 52nd Annual Meeting of the European Association for the Study of Diabetes (EASD) in Munich, Germany.
Pfizer and Merck plan to submit an NDA in the U.S. for ertugliflozin and the two fixed-dose combination tablets, ertugliflozin/Januvia and ertugliflozin/metformin, by 2016 end.
Merck has several late-stage candidates in its pipeline targeting multiple disease areas such as atherosclerosis, cancer, diabetes and cardiovascular diseases. The company has more than 10 candidates in phase III development. Some of the important candidates include MK-0859 (anacetrapib – cholesterol management – phase III), verubecestat (Alzheimer’s disease – phase III) and Zinplava (bezlotoxumab).
Zacks Rank & Key Picks

Both Merck and Pfizer currently carries a Zacks Rank #3 (Hold). A couple of better-ranked stocks in health care sector are ANI Pharmaceuticals (NASDAQ:ANIP) and Johnson & Johnson (NYSE:JNJ) . While ANI Pharmaceuticals sports a Zacks Rank #1 (Strong Buy), Johnson & Johnson carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Confidential from Zacks

Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>



PFIZER INC (PFE): Free Stock Analysis Report

JOHNSON & JOHNS (JNJ): Free Stock Analysis Report

MERCK & CO INC (MRK): Free Stock Analysis Report

ANI PHARMACEUT (ANIP): Free Stock Analysis Report

Original post

Zacks Investment Research

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.